Literature DB >> 1229807

Serum insulin, insulin antibodies and insulin requirement in the first period of insulin treatment in non-insulin resistant diabetics.

A Lev-Ran, L Ratt, N Gersht.   

Abstract

Twelve insulin-sensitive diabetics were studied for 200 days after the initiation of mixed beef-pork NPH insulin. Normalization of the fasting blood glucose was not accompanied by any elevation in the pre-treatment fasting immunoreactive insulin level. Insulin antibodies appeared in 2 patients on the second week of insulin treatment, in 6 others within 87 days. In 4 patients no antibodies were found 200 days after the start of insulin. The appearance of antibodies was accompanied in two patients by a decrease in insulin requirement, in others there was no change. When antibodies were present, the total maximum insulin binding capacity was 4 to 12 U/l, but the total insulin constituted only 3 to 36% of the binding capacity. Insulin wastage caused by the destruction of the immune complexes was calculated to be 0.35 to 5.6 U/die only, and this explains the negligible effect of insulin antibodies on insulin requirement in non-resistant patients.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1229807     DOI: 10.1007/bf02581113

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  12 in total

1.  Quantitative aspects of the reaction between insulin and insulin-binding antibody.

Authors:  S A BERSON; R S YALOW
Journal:  J Clin Invest       Date:  1959-11       Impact factor: 14.808

2.  Circulating C-peptide immunoreactivity. Studies in normals and diabetic patients.

Authors:  M B Block; M E Mako; D F Steiner; A H Rubenstein
Journal:  Diabetes       Date:  1972-10       Impact factor: 9.461

3.  Serum-insulin levels in patients on insulin.

Authors:  K E Quickel; J M Feldman
Journal:  Lancet       Date:  1971-07-24       Impact factor: 79.321

4.  Sequential changes in beta-cell function in insulin-treated diabetic patients assessed by C-peptide immunoreactivity.

Authors:  M B Block; R L Rosenfield; M E Mako; D F Steiner; A H Rubenstein
Journal:  N Engl J Med       Date:  1973-05-31       Impact factor: 91.245

5.  Plasma immunoreactive insulin patterns in insulin-treated diabetics. Studies during continuous blood glucose monitoring.

Authors:  G D Molnar; W F Taylor; A L Langworthy
Journal:  Mayo Clin Proc       Date:  1972-10       Impact factor: 7.616

6.  Serum insulin levels following administration of exogenous insulin.

Authors:  S Ginsberg; M B Block; M E Mako; A H Rubenstein
Journal:  J Clin Endocrinol Metab       Date:  1973-06       Impact factor: 5.958

7.  Disappearance of bovine insulin from plasma in diabetic and normal subjects.

Authors:  P J Palumbo; W F Taylor; G D Molnar; W N Tauxe
Journal:  Metabolism       Date:  1972-09       Impact factor: 8.694

8.  Determination of free and antibody-bound insulin in insulin treated diabetic patients.

Authors:  L G Heding
Journal:  Horm Metab Res       Date:  1969-05       Impact factor: 2.936

9.  Insulin binding and free insulin in serum of insulin-treated diabetics.

Authors:  A Lev-Ran; L Ratt
Journal:  Horm Metab Res       Date:  1973-03       Impact factor: 2.936

Review 10.  [Insulin-binding antibodies and insulin resistance (author's transl)].

Authors:  W Waldhäusl
Journal:  Wien Klin Wochenschr       Date:  1973-12-21       Impact factor: 1.704

View more
  1 in total

1.  The immunogenic properties of a highly purified insulin preparation.

Authors:  N T Manning; M I Drury
Journal:  Ir J Med Sci       Date:  1979-12       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.